Publications
Specialty
Search
The Dermatologist
06/11/2024
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
Psych Congress Network
06/11/2024
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
ePlasty
06/11/2024
This Case Q&A on sunburn discusses its pathophysiology, treatment options, the role of ultraviolet radiation, and the evolutionary benefit of skin pigmentation.
First Report Managed Care
06/11/2024
Research highlights differing HIV risk behaviors and service use between urban and rural adolescent sexual minority males in the US, emphasizing the need for targeted interventions to reduce infection rates in rural areas where access to sexual health care services may be limited.
Oncology
06/11/2024
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
Oncology
06/11/2024
According to results from a phase 2 study, adebrelimab plus chemotherapy and sequential thoracic radiotherapy demonstrated promising efficacy and safety among patients with extensive-stage small-cell lung cancer.
Oncology
06/11/2024
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously untreated diffuse large B-cell lymphoma.
Psych Congress Network
06/11/2024
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
EP Lab Digest
06/11/2024
CAMBRIDGE, Mass., June 06, 2024 -- Anthos Therapeutics, Inc., a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences (BXLS), today provided an update on the transition of patients in the open-label extension (OLE) portion of the AZALEA-TIMI 71
EP Lab Digest
06/11/2024
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
APP Institute Dermatology
06/11/2024
Editorial Advisory Board Member Lakshi Aldredge, NP, shares what's in store for our new APP Institute Dermatology microlearning site.
Oncology
06/11/2024
According to a phase 2 trial, low-dose azacitidine plus venetoclax was found to be a feasible maintenance strategy for patients with acute myeloid leukemia following intensive and low-intensity induction.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
Anteris Provides Data Update on First-in-Human Study of DurAVR THV Presented at New York Valves 2024
06/11/2024
Anteris Technologies Ltd, a structural heart company developing DurAVR THV, a balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/11/2024
“There are many stressors in cardiovascular medicine, including an aging cardiovascular patient population and workforce, and a decrease in cardiologists entering the field because of insufficient fellowship positions despite the rising demand. This contributes to workforce shortages, additional stress and potential for burnout among cardiovascular health professionals,” said Laxmi Mehta, MD.
First Report Managed Care
06/11/2024
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA, MSPH, senior vice president of CVS Specialty Operations, the audience gained fresh insights into combating nonadherence and learned new strategies to improve patient care.
Cath Lab Digest, CardioVascular, Journal of Invasive Cardiology
06/11/2024
A new study by investigators at Massachusetts General Hospital (MGH) reveals an important step to help the human heart regenerate after myocardial infarction (MI). For the first time, the researchers compared the formation of scar tissue in the injured hearts of zebrafish and mice, discovering how to potentially reverse the permanent scarring that is so damaging to mammal hearts.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/11/2024
The Iocyte AMI-3 trial is a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of FDY-5301 in reducing cardiovascular death and heart failure events in anterior STEMI patients undergoing PCI.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/11/2024
Passive heat exposure was enough to increase myocardial blood flow in all participants, regardless of age and health status, creating significant stress on the heart. The authors observed asymptomatic heat-induced myocardial ischemia in some participants with CAD, suggesting that these adults may benefit from minimizing cardiac strain during extreme heat by staying cool.
Integrated Healthcare Executive
06/11/2024
Treatment with nirmatrelvir-ritonavir did not significantly shorten the time to sustained alleviation of symptoms in patients with COVID-19 compared with placebo, according to a study published in The New England Journal of Medicine.
Podiatry Today, Wound Care, Podiatry
06/11/2024
This author discusses his SAWC Spring poster.